Objectives. The aim of this study was to assess the overall prevalence of pulmonary hypertension (PH) in an unselected MCTD cohort and review the current knowledge with a systematic database search.
Introduction
The concept of MCTD as a separate immune-mediated CTD was first introduced by Sharp et al. in 1972 [1] . MCTD is characterized by serum autoantibodies directed against ribonucleoprotein (anti-RNP) and distinct clinical features including RP, puffy hands, arthritis, pleuritis, pericarditis, myositis, oesophageal dysmotility and pulmonary fibrosis [25] . Although some of the clinical features are also present in other CTDs, the combination of clinical features with a positive test for anti-RNP appears to be unique for MCTD.
Recently we completed the nationwide Norwegian MCTD study and presented the first data on the epidemiology of the disease [4] and the frequency and severity of lung involvement [5] . Here the aim was to estimate the prevalence and mortality of pulmonary hypertension (PH) in the cohort and review the current knowledge on PH in MCTD.
Methods
The study was approved by the Regional Committee for Research Ethics (REK) in the Southern and Eastern Norway Regional Health Authority and the Norwegian Social Science Data Services (NSD). The design of this nationwide MCTD study and the inclusion procedures have previously been described in detail [4, 5] . Briefly, patients were included from all 16 Norwegian public hospitals that have a department of rheumatology. The inclusion of patients started in March 2005 and ended in December 2008. Inclusion of patients in the MCTD cohort was based on the five following criteria: age 518 years, a clinical diagnosis of MCTD verified by a rheumatologist, exclusion of other CTDs, a positive serum anti-RNP antibody test in high titre and fulfilment of at least one of three criteria sets (Sharp [6] , Alarcó n-Segovia [7] and/or Kasukawa [8] ) for MCTD.
The study protocol included echocardiography, highresolution computed tomography (HRCT) evaluated by two experienced chest radiologists [5] , pulmonary function tests (PFTs) according to published guidelines [5] , dyspnoea evaluation by the New York Heart Association (NYHA) functional classification [5] , 6-minute walking distance test (6MWT) [5] and blood tests, including N-terminal pro-brain natriuretic peptide (NT-proBNP). NT-proBNP is a serum biomarker with known prognostic value for PH [9] . NT-proBNP in plasma was determined by an electrochemiluminescence immunoassay on a modular platform (Roche Diagnostics, Basel, Switzerland) with normal reference value <25 pmol/l.
Screening for PH
The echocardiographic examination was performed by a cardiologist at the patient's local hospital. The pulmonary artery systolic pressure (PASP) was estimated by Doppler echocardiography by measuring the maximum tricuspid regurgitation jet velocity (TRV). Assumption of right atrial pressure (RAP) was estimated by the size and respiratory variation of the flow in the inferior vena cava [10] or using a fixed value of 510 mmHg in patients without right heart failure. PASP was estimated with the simplified Bernoulli equation: PASP = (4 Â TRV 2 ) + RAP [11] . PASP >40 mmHg was set as a predefined cut-off value for performing rightsided heart catheterization (RHC). Precapillary PH was defined according to the 2009 European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines [11] and patients with PH were further classified as pulmonary arterial hypertension (PAH) (group 1.4.1) or as PH-ILD (group 3.2) according to the Dana Point classification [12] . PAH was defined by the absence of interstitial lung involvement on HRCT scan and/or forced vital capacity (FVC) 570% of predicted [13] , while PH-ILD was defined by interstitial lung involvement on HRCT affecting >5% of the lung and a restrictive pattern defined by an FVC <70% of predicted on PFTs [13] . Other underlying causes of PH were excluded.
After enrolment, all the patients were followed up according to routine clinical care at their local hospitals until 31 December 2011. Data about deaths were gathered from the Norwegian Statistical Institute (http://www.ssb. no) and from local hospitals.
Statistical analysis
The statistical software SPSS/PASW version 19 was used.
Review of current knowledge on prevalence of PH in MCTD
The OvidSP MEDLINE and OvidSP EMBASE databases (http://ovid.com) were searched. Studies concerning at least 10 patients were included in the analysis and only articles or abstracts in English, German or Scandinavian languages were reviewed.
Results
The study cohort consisted of 147 Caucasian MCTD patients, of whom 97% fulfilled at least two of the three MCTD criteria sets [4, 68] and 113 (77%) were women. At inclusion, the mean disease duration was 10.2 years (S.D. 8.4) and the clinical follow-up lasted for a mean 5.6 years (S.D. 0.9).
Three of 147 patients had PH at inclusion (Table 1) . One (patient 1) had PAH (without ILD) and the other two (patients 2 and 3) had PH-ILD, with HRCT findings consistent with severe lung fibrosis [5] . All the other 144 patients were referred to echocardiography screening when enrolled in the study. Two patients refused to do the echocardiography, but neither had symptoms of PH. The remaining 142 patients were included in the screening. Six had a PASP >40 mmHg on Doppler echocardiography and were referred to RHC. One patient refused but the other five were examined by RHC and none of them had PH [mean mPAP 16 mmHg (S.D. 6.7) and mean PVR 202 dynÁsÁcm À5 (S.D. 105)].
Assessment of PH during follow-up
At least 308 echocardiographic investigations were performed as part of inclusion and during the clinical www.rheumatology.oxfordjournals.org follow-up of the MCTD cohort. Sixty-four per cent of the patients were examined by echocardiography at least once during the follow-up period, some as a routine screening, while others were examined due to clinical suspicion of PH. Two additional patients were diagnosed with PH during the follow-up period. Patient 4 was referred to echocardiography and RHC because of rapidly progressive dyspnoea and patient 5 was identified at routine clinical screening (Table 1 ). Of the five PH patients, two (40%) were defined as PAH (group 1.4.1) [12] , while three (60%) had PH-ILD (group 3.2) [12] . None of them had PH owing to left heart disease (group 2) [12] or chronic thromboembolism (group 4) [12] .
Twelve (8.2%) of the 147 patients in the cohort died during the follow-up period. Three of the five patients identified as having PH (patients 24) died from right ventricular failure. The causes of death in the nine other deceased patients were ILD (n = 2), coronary heart disease (n = 2), cancer (n = 4) and unknown (n = 1). Except for the four patients who died of cancer, all the deceased patients had echocardiograms without any signs of PH shortly before death. The point prevalence of PH in the Norwegian MCTD cohort study at inclusion was 2.0% (3/ 147) and during the period from 2005 to 2011 the total frequency of PH in the cohort was 3.4% (5/147).
Review of current knowledge on PH in MCTD
The total number of references using the predefined search strategy terms was 135 in OvidSP MEDLINE and 255 in OvidSP EMBASE, resulting in 263 unique references. Only 4 of these 263 references fulfilled the predefined criteria for assessing the prevalence of PH in MCTD [2, 3, 14, 15] (Table 2 ). Three of the four studies were cohort follow-up studies from a single centre and estimated the prevalence of PH as 2324% [2, 3, 14] . The fourth study was a multicentre screening study that estimated the prevalence of PH as 19% solely based on echocardiography [15] . Myositis was defined as increased serum creatine kinase (CK) and proximal muscle weakness, in some cases confirmed by muscle biopsy and/or electromyograph.
Discussion
Our data suggest that the prevalence of PH in MCTD is lower than anticipated from the previous reports [2, 3, 14, 15] and is possibly explained by several factors. The first and probably most important is the selection of the study population. While previous studies [2, 3, 14] assessed PH in MCTD patients referred to tertiary care units, we screened an unselected MTCD population [4, 5] . Due to the free, easy access of public health service, the compulsory national registry of citizens and the computerbased hospital diagnosis registries in Norway, we were able to enrol and follow all available MCTD patients in the country. Hence we believe that our data reflect the true prevalence of PH in unselected patients with established MCTD. Second, the MCTD case assignment was different. The earlier studies either used no MCTD criteria sets [2, 14] or one only single set (Kasukawa [3] and Alarcó n-Segovia [15]), whereas we applied all of the three most common MCTD criteria sets [68] . Third, the mean follow-up time (5.6 years) in our study was shorter than the 15 and 6.3 years previously reported [2] . Since two new PH cases were identified during follow-up, we cannot rule out that the frequency of PH may increase over time. Fourth, our female:male ratio was 3.3, whereas the others reported ratios above 10 [2, 3, 14] . This is relevant as PH seems to be more prevalent in women [16, 17] . Fifth, and finally, since African Americans appear to develop PH more often than Caucasians, it may be relevant that all our patients were Caucasians, whereas Burdt et al. Another issue is the possible difference in the stringency of the PH diagnosis between the current and the previous studies. Here, PH was defined according to the RHC criteria set forth in the 2009 European Society of Cardiology and European Respiratory Society Guidelines [11] . Three of the previous studies also used RHC to define PH, but it is not clear if they also included patients who only had PH by the now abandoned, exercise-related definition of PH [11] . The fourth study defined PAH solely by Doppler echocardiography [15] . Noteworthy, all the MCTD patients in the previous PH studies [2, 3, 14] were defined as having PAH, although the data show that many of them had severe ILD. Importantly, MCTD patients may well have both ILD and pulmonary vascular disease and it may be difficult to establish whether PH is an isolated vascular disease (PAH) independent of ILD or whether it is caused by ILD. To complicate the issue further, it is even possible that both PH and ILD are secondary to pulmonary vasculopathy [13] . Hence it is currently uncertain to what extent PAH and PH-ILD represent two different phenotypes of PH in MCTD. Our own study is unable to shed new light on these issues, owing to the low number of PH patients identified.
There are at least two potential limitations of the current study. The first is that the MCTD patients included were followed up according to the routine clinical practice at the local department of rheumatology rather than by a standardized protocol. Typically the local routines included clinical assessment, PFT, 6MWT and NT-proBNP. Although there are no guidelines on repeated echocardiography in MCTD, at least 64% of the patients in the cohort were examined by at least one echocardiograph during follow-up. This rather high frequency of echocardiographic controls does not rule out the possibility that cases of PH may have gone unnoticed in our cohort. It was nonetheless reassuring that none of the deaths during follow-up was attributable to undiagnosed PH.
The second potential weakness is that echocardiography and not RHC was used as the primary screening tool for PH. The correlation between pulmonary pressures determined by echocardiography and by RHC is modest [18, 19] , with a potential loss of true PH cases. However, the initial PH case finding strategy did not rely on echocardiography alone but was combined with a clinical assessment, PFTs, HRCT and NT-proBNP measurements.
While our prevalence data differ from the four reports detailed in Table 1 [2, 3, 14, 15] , they appear to be in accordance with data from the UK national registry of all incident connective tissue-associated PH cases diagnosed between 2001 and 2006 [20] . A total of 36 MCTD-PH patients were identified during a 5-year follow-up of the 60 million UK population (about 0.6 MCTD-PH per million). This prevalence rate is in the same range as that identified in our cohort, with five MCTD-PH cases during a 5.6-year follow-up of the 4.9 million Norwegian population (about 1.0 MCTD-PH per million).
Rheumatology key messages
. PH in MCTD was much lower in this study than expected from earlier small-cohort studies. . The study confirms the severity of PH in MCTD.
